Literature DB >> 8704199

Humoral immune response limits gene therapy in canine MPS I.

R Shull, X Lu, I Dubé, C Lutzko, S Kruth, A Abrams-Ogg, H P Kiem, S Goehle, F Schuening, C Millan, R Carter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8704199

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

2.  Identification of noncollagenous sites encoding specific interactions and quaternary assembly of alpha 3 alpha 4 alpha 5(IV) collagen: implications for Alport gene therapy.

Authors:  Jeong Suk Kang; Selene Colon; Thomas Hellmark; Yoshikazu Sado; Billy G Hudson; Dorin-Bogdan Borza
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

3.  Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses.

Authors:  Elena L Aronovich; Jason B Bell; Lalitha R Belur; Roland Gunther; Brenda Koniar; David C C Erickson; Patricia A Schachern; Ilze Matise; R Scott McIvor; Chester B Whitley; Perry B Hackett
Journal:  J Gene Med       Date:  2007-05       Impact factor: 4.565

Review 4.  A review of gene therapy in canine and feline models of lysosomal storage disorders.

Authors:  Allison M Bradbury; Brittney L Gurda; Margret L Casal; Katherine P Ponder; Charles H Vite; Mark E Haskins
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-11       Impact factor: 5.032

Review 5.  Gene therapy for neurologic manifestations of mucopolysaccharidoses.

Authors:  Daniel A Wolf; Sharbani Banerjee; Perry B Hackett; Chester B Whitley; R Scott McIvor; Walter C Low
Journal:  Expert Opin Drug Deliv       Date:  2014-12-16       Impact factor: 6.648

6.  Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.

Authors:  Daniel A Wolf; Andrew W Lenander; Zhenhong Nan; Lalitha R Belur; Chester B Whitley; Pankaj Gupta; Walter C Low; R Scott McIvor
Journal:  Neurobiol Dis       Date:  2011-03-17       Impact factor: 5.996

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 8.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

9.  Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

Authors:  Mayra F Garcia-Rivera; Leah E Colvin-Wanshura; Matthew S Nelson; Zhenhong Nan; Shaukat A Khan; Tyson B Rogers; Indrani Maitra; Walter C Low; Pankaj Gupta
Journal:  Brain Res Bull       Date:  2007-08-06       Impact factor: 4.077

10.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.